Company news
Guangxi Wuzhou Zhongheng Group Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(600252)"Guangxi Wuzhou Zhongheng Group Co., Ltd."Announcement on Proposed Transfer by Public Listing of Equity Interest in an Investee Company by the Wholly-owned Subsidiary Zhongheng Yixin
November 10, 2026
(600252)"Guangxi Wuzhou Zhongheng Group Co., Ltd."Announcement on Progress of Government's Acquisition and Reserve of Land Owned by Controlled Sub-subsidiary
November 2, 2026
(600252)"Guangxi Wuzhou Zhongheng Group Co., Ltd."Announcement on Progress in Repurchasing Shares through Call Auction in 2026
November 2, 2026
(600252)"Guangxi Wuzhou Zhongheng Group Co., Ltd."Report for Q3 2026
October 30, 2026
(600252)"Guangxi Wuzhou Zhongheng Group Co., Ltd."Announcement on Provision of Guarantee by Controlled Subsidiary for Financing Credit Facilities of Its Wholly-Owned Subsidiary
October 23, 2026
(600252)"Guangxi Wuzhou Zhongheng Group Co., Ltd."Announcement on Providing Guarantee for Controlled Subsidiary Guangxi Tianqijiahua Industrial Co., Ltd.
October 8, 2026
(600252)"Guangxi Wuzhou Zhongheng Group Co., Ltd."Announcement on Proposed Public Listing for Sale of Certain Assets by the Controlled Subsidiary Lummy Pharmaceutical
October 8, 2026
(600252)"Guangxi Wuzhou Zhongheng Group Co., Ltd."Announcement on Progress of Government's Acquisition and Reserve of Land Owned by Controlled Sub-subsidiary
October 8, 2026
(600252)"Guangxi Wuzhou Zhongheng Group Co., Ltd."Announcement on Progress in Repurchasing Shares through Call Auction in 2026
October 8, 2026
Indicative Announcement on Postponement of Election of New Board of Directors
September 24, 2026
Announcement on Resignation and Appointment of Senior Executive
September 17, 2026
Announcement on Obtaining the Approval Notice for Marketing Application of a Chemical API by a Controlled Sub-subsidiary
September 14, 2026
Announcement on Initial Repurchase of Shares through Call Auction in 2026 and Progress in Share Repurchase
August 31, 2026
Announcement on Resolutions of the 47th Meeting of the 10th Board of Directors
August 30, 2026
Announcement on Extension of the Term of Nanning Zhongheng Tongde Pharmaceutical Industry Investment Fund Partnership (Limited Partnership)
August 17, 2026
Announcement on Resolutions of the 4th Extraordinary General Meeting in 2026
August 14, 2026
Announcement on Obtaining Drug Registration Certificate by Controlled Subsidiary
August 10, 2026
Announcement on Progress of Government's Acquisition and Reserve of Land Owned by a Controlled Sub-subsidiary
August 3, 2026
Announcement on Obtaining a Commitment Letter for a Special Loan for Share Repurchase from a Financial Institution
July 30, 2026
Notice on Convening the 4th Extraordinary General Meeting in 2026
July 27, 2026
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026
July 24, 2026
Announcement on the Signing of the "Drug Marketing Authorization Transfer Agreement" by a Controlled Subsidiary
July 23, 2026
Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders of Unrestricted Shares Concerning Share Repurchase
July 20, 2026
Announcement on Semi-annual Performance Forecast for 2026
July 14, 2026
Announcement on Rectification Report in Response to the Warning Letter Issued by China Securities Regulatory Commission Guangxi Bureau
July 10, 2026
Announcement on Reply to the Shanghai Stock Exchange's Information Disclosure Supervisory Inquiry Letter on the Company's 2025 Annual Report
July 7, 2026
Announcement on Progress in Government Land Reserve of the Land of Controlling Sub-subsidiary
July 2, 2026
Announcement on Appointment of Chief Financial Officer
June 30, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
June 25, 2026
Announcement on Holding Sub-subsidiary Obtaining Medical Device Registration Certificate
June 12, 2026
Announcement on Expiry and Non-Renewal of the Voting Rights Entrustment Agreement Signed Between the Company and a Shareholder of Lummy Pharmaceutical
June 9, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
June 5, 2026
Announcement on Progress in Government Land Reserve of the Land of Holding Sub-subsidiary
June 1, 2026
Announcement on Completing Deregistration of Zhongheng Group Wuzhou Pharmaceutical (Hong Kong) Co., Ltd.
May 20, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
May 19, 2026
Announcement on Holding Sub-subsidiary Obtaining Approval for Marketing of Chemical APIs
May 15, 2026
Announcement on Completion of Private Investment Fund Filing by the Venture Capital Fund Established with Investment Participation of the Holding Subsidiary
May 11, 2026
Announcement on Convening the 2025 Annual Performance Briefing
May 8, 2026
Report for Q1 2026
April 29, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
April 28, 2026
Announcement on Completion of Liquidation and Deregistration of Guangxi Lihe Zhongheng Pharmaceutical Investment Partnership (Limited Partnership)
April 22, 2026
Announcement on Progress in Government Land Reserve of the Land of Controlling Sub-subsidiary
April 1, 2026
Announcement on Resignation of Directors and Financial Person in Charge and the Election of Employee Representative Directors
March 31, 2026
Notice on Convening the 2025 Annual General Meeting
March 30, 2026
Announcement on Holding Subsidiary Obtaining Notice of Approval for Supplementary Drug Application
March 24, 2026
Announcement on Correction and Retroactive Adjustment of Accounting Errors in the Previous Period
March 20, 2026
Announcement on Signing of a Supplemental Agreement Regarding Government Land Reserve of the Land Matters of Controlling Sub-subsidiary
March 17, 2026
Announcement on Resignation of Director
March 13, 2026
Announcement on Holding Subsidiary’s Participation in Establishment of a Venture Capital Fund
March 12, 2026
Announcement on Resolutions of the 37th Meeting of the 10th Board of Directors
March 2, 2026